Email this article 
Estimation of clinical efficiency of topical combination therapy patients with pyoderma complicated eczema
- Authors: Okhlopkov V.A.1, Zubareva E.Y.1, Novikov Y.A.1, Sukach M.S.1, Repina T.V.2, Lekavitchus I.Y.2, Grankina N.V.2
-
Affiliations:
- Omsk State Medical Academy
- Clinical dermatovenerologic dispensary
- Issue: Vol 90, No 3 (2014)
- Pages: 121-127
- Section: DRUG TREATMENT IN DERMATOVENEROLOGY
- URL: https://vestnikdv.ru/jour/article/view/42
- DOI: https://doi.org/10.25208/0042-4609-2014-90-3-121-127
- Cite item
Full Text
Abstract
About the authors
V. A. Okhlopkov
Omsk State Medical Academy
Author for correspondence.
Email: ochlopkov@omsk-osma.ru
Russian Federation
E. YU. Zubareva
Omsk State Medical Academy
Email: noemail@neicon.ru
Russian Federation
YU. A. Novikov
Omsk State Medical Academy
Email: noemail@neicon.ru
Russian Federation
M. S. Sukach
Omsk State Medical Academy
Email: noemail@neicon.ru
Russian Federation
T. V. Repina
Clinical dermatovenerologic dispensary
Email: noemail@neicon.ru
Russian Federation
I. YU. Lekavitchus
Clinical dermatovenerologic dispensary
Email: noemail@neicon.ru
Russian Federation
N. V. Grankina
Clinical dermatovenerologic dispensary
Email: noemail@neicon.ru
Russian Federation
References
- Izadpanah A., Gallo R.L. Antimicrobial peptides. J Am Acad Dermatol 2005; 52 (3Pt1): 381-390.
- Wolff K., Goldsmith L.A., Katz S.I. et al. Fitzpatrick’s dermatology in general medicine: v 3 t. Per. s angl.; obshch. red. akad. A.A. Kubanovoy. M.: Izd-vo Panfilova; BINOM, Laboratoriya znaniy, 2012; T.3: s. 1841-1847.
- Bakulev A.L., Kravchenya S.S., Murashkin N.N. et al. Microbial eczema: new potential of combined topical treatment. Vestn Dermatol Venerol 2011; 6: 98-104
- Sohn A., Francel A., Patel R.V., Goldenberg G. Eczema. Mt Sinai J Med 2011; 78 (5): 730-739.
- Chang C., Keen C.L., Gersbwin M.E. Treatment of eczema. Clin Rev Allergy Immunol. 2007; 35 (3): 204-225. Литература
- Hoare C., Li Wan Po A., Williams H. Systemic review of treatments for atopic eczema. Health Technol Assess 2000; 4 (37): 1-191.
- Okovityy S.V., Ivkin D.Yu. Mupirotsin: klinicheskoe primenenie. Consilium medicum 2011; (4): 3-10.
- Sutherland R., Boon R.J., Griffin K.E. et al. Antibacterial activity of mupirocin (pseudomonic acid) a new antibiotic for topical use. Antimicrob Agent Chemother 1985; 27 (4): 495-498.
- Leyden J.J. Mupirocin - a new topical antibiotic. Semin Dermatol 1987; (6): 48-54.
- Pappa K.A. The clinical development of mupirocin. J Am Acad Dermatol 1990; 22 (5 Pt 1): 873-879.
- Bogdanovich T.M., Strachunskiy L.S. Mupirotsin: unikal'nyy antibiotik dlya mestnogo primeneniya. Clinical Microbiology and Antimicrobial Therapy 1999; 1 (1): 57-65
- Prakticheskoe rukovodstvo po antiinfektsionnoy khimioterapii. Pod red L.S.Strachunskogo, Yu.B. Belousova, S.N. Kozlova, M.: NIIAKh SGMA, 2002: 586 S.
- Annigeri R., Conly J., Vas S. at al. Emergence of mupiricin-resistant Staphylococcus aureus in chronic peritoneal dialysis patients using mupirocin prophylaxis to prevent exit-site infection. Perit Dial Int 2001; 21 (6): 554-559.
- Vas S.I., Conly J., Bargman J.M., Oveopoulos D.G. Resistence to mupirocin no indication of it to date while using mupirocin ointment for prevention of Staphylococcus aureus exit-site infections in peritoneal dialysis patients. Perit Dial Int 1999; 19 (4): 313-314.
- Savant S., Janaki V.R., Mittal R.R. et al. Evaluation of safety and efficacy of supirocin-B (mupirocin 2% + betamethasone dipropionate 0.05%) in infected dermatosis - a post marketing study. J Indian Med Assoc 2000; 90 (4): 194-195.
